Home / Journals International Journal of Pharmacy and Chemistry / Treatment of Alzheimer’s Disease
Treatment of Alzheimer’s Disease
Submission DeadlineAug. 30, 2020

Online submission system: http://www.sciencepublishinggroup.com/login

Lead Guest Editor
Zeynep Özdemir
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, Malatya, Turkey
Guest Editors
  • Mehtap Uysal
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erzincan Binali Yildirim University, Malatya, Turkey
  • Azime Berna Özçelik
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Malatya, Turkey
  • İnci Selin Doğan
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Karadeniz Technical University, Malatya, Turkey
  • Mehmet Abdullah Alagöz
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, Malatya, Turkey
  • Arzu Karakurt
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, Malatya, Turkey
Introduction
Alzheimer's disease (AD) is a fatal neurodegenerative disease characterized by impaired ability to perform daily activities of the person and progressive cognitive dysfunctions and various neuropsychiatric symptoms in the later stages of the disease. The prevalence of AD, the most common form of dementia seen in the elderly, doubles every five years, reaching 1% at 60 years of age to 30% at 85 years of age (3). According to the results of the epidemiological studies on AD, it is estimated that the number of patients is approximately 5 million in the United States and 24 million in the world. Estimates are that this number will double in 20 years to reach 42 million in 2020 and 81 million in 2040. Although the physiopathology of AD is not yet fully understood, it is thought that the disease is caused by the indetected disappearance of brain cells and three main hypotheses (cholinergic hypothesis, amyloid hypothesis, Tau hypothesis) about the formation of the disease are suggested.
Anticholinesterases are used in the treatment of diseases such as myasthenia gravis, atons in the gastrointestinal tract, glaucoma, Alzheimer. These compounds are also used as nerve gases and insecticides. Several cholinesterase inhibitors such as tacrine, donepezil, rivastigmine, galantamine and huperzine A have been shown to slow the progression of disease in AD.
Aims and Scope:
  1. Cholinergic hypothesis
  2. Amiloid Hypothesis
  3. Tau Hypothesis
  4. Cholinesterase inhibitors
  5. Multitarget drugs for Alzheimer treatment
  6. MAO-B inhibitors on treatment of Alzheimer
Guidelines for Submission
Manuscripts should be formatted according to the guidelines for authors
(see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=330).

Please download the template to format your manuscript.

ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186